Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

SLN360

Oligonucleotide (siRNA) · Gene silencing: apolipoprotein(a) (LPA) · developed by Silence Therapeutics

Phase 1 Most advanced trial (none active)
1 Registered trials

What is SLN360?

SLN360 is a small interfering RNA (siRNA) administered by subcutaneous injection that targets apolipoprotein(a) to reduce lipoprotein(a) levels. It is studied in hyperlipidemias and dyslipidemias.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Oligonucleotide (siRNA)
Targets
apolipoprotein(a) (LPA)
Mechanism
Gene silencing: apolipoprotein(a) (LPA)
Pathways
lipoprotein metabolism
Therapy area
Metabolic
Developer
Silence Therapeutics plc
In trials of
MEDP
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
FBX7PTD863

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04606602 Phase 1 Hyperlipidemias Completed MEDP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

DyslipidemiasElevated Lp(a)Hyperlipidemias

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.